Member Info for Schlum

This will be significantly positive news for £4 m market cap Fusion.

Nigel will be giving his N4 Pharma presentation this afternoon at Mello, so hoping for good news. Toodle pip!

We do need a decent news update to keep the upwards momentum.

Adrian commented that publication of the joint work with NCI was being peer reviewed and due soon. As of his last interview.

Or market makers looking to fill a large order.

With 30 industry meetings over the last two days alone, it would not surprise me.

The interest being generated by N4P, considering the 30 odd meetings scheduled at the Pharma conference is really impressive.

It seemsimport tariffs in the US would be a boon to Synt, and if a much needed residential construction boom can be orchestrated, so much the better.

The signing off of licensing deals, will be the catalyst to send the SP sharply higher.

Well if an auction develops to buy the whole ship, just as she finally sets sail; the bidding will have to start at 10 p +, I would imagine.

Just rewatched the presentation; Adrian commented that he is comfortable in projecting a return to profitability next year.

Of note was his comment that joint publication of the work with the National Cancer institute is currently being peer reviewed and due soon.

Finally he commented that the Fusion share price undervalues the company by many multiples.

Altogether positive.

According to the CEO cash is sufficient through to 2nd half fiscal year 2026, as gross margin increases the company is on track to be cash flow positive by that time.

Clearly cash burn is a concern, however validation by the Nat. Cancer Institute of America of their joint work with Fusion , may come within a year and transform the company’s prospects.

All investment is risk versus reward.

I read yesterday of how doctors are turning to phage treatment in place of antibiotics, for hard to treat super bug infections in patients.

I do not confess to understand this treatment but note that Fusion seems to be at the forefront of research with their phage library.

May have gotten the wrong idea here but it seems intriguing.

The presentation was well prepared and illustrated the potential for a dramatic increase in the share price( 20 - 50 x, according to Nigel). Of course that uplift is dependent upon finding the right development partners.

The research. Of many years is now on the cusp of transforming the company.

The current SP does indeed seem far too low.

The updated website is very professional and a shop window.

Presentation by the company scheduled for 2pm today.

So many potential licensing deals , it will be good to get updates on their progress. One coming close to completion will be very good to hear.

The director’s ,pricing their new share options at many multiples of the current price ,is no coincidence.

Crazy world we live in, this product will sell well.

I think you will find Image Scan is far from a turkey!

There is a demand for the right Modern Water products, if the management could just get its act together.

On the contrary I have expectations that our Californian joint venture may announce big pharma interest at any time.

The risk/reward here looks very interesting. There again I am an optimist at heart.